HASSELT, Belgium--(BUSINESS WIRE)--MabCure, Inc. (OTCBB:MBCI) (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the June 4, 2009 edition of BioWorld® Today, biotech’s most respected news source for over seventeen years.
